Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Other Non-Current Liabilities (2021 - 2025)

BioAtla (BCAB) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 419.71% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $19.8 million, up 419.71%, while the annual FY2025 figure was $19.8 million, 419.71% up from the prior year.
  • Other Non-Current Liabilities hit $19.8 million in Q4 2025 for BioAtla, roughly flat from $19.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $19.8 million in Q4 2021 and bottomed at $2.2 million in Q2 2025.
  • Average Other Non-Current Liabilities over 5 years is $17.7 million, with a median of $19.8 million recorded in 2021.
  • On a YoY basis, Other Non-Current Liabilities climbed as much as 419.71% in 2025 and fell as far as 88.75% in 2025.
  • BioAtla's Other Non-Current Liabilities stood at $19.8 million in 2021, then changed by 0.0% to $19.8 million in 2022, then changed by 0.0% to $19.8 million in 2023, then plummeted by 80.76% to $3.8 million in 2024, then soared by 419.71% to $19.8 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $19.8 million, $19.8 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.